Literature DB >> 7524507

Autoimmune disease. A problem of defective apoptosis.

J D Mountz1, J Wu, J Cheng, T Zhou.   

Abstract

Human autoimmune diseases share the common feature of an imbalance between the production and destruction of various cell types including lymphocytes (SLE), synovial cells (RA), and fibroblasts (scleroderma). Patients with SLE have increased levels of soluble Fas that inhibit proper apoptosis of lymphocytes. In animal models of autoimmune diseases, mutations of genes involved in apoptosis including Fas, Fas ligand, and the hematopoietic cell phosphatase gene have been identified. Oncogenes, including bcl-2, p53, and myc, that regulate apoptosis are also expressed abnormally. Potent inducers of apoptosis including steroids, azathioprine, cyclophosphamide, and methotrexate are the most efficacious therapies for autoimmune disease currently known. Specific therapies that induce apoptosis without incurring side effects should improve treatment of autoimmune disease.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7524507     DOI: 10.1002/art.1780371002

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  41 in total

1.  Changes in apoptotic gene expression in lymphocytes from rheumatoid arthritis and systemic lupus erythematosus patients compared with healthy lymphocytes.

Authors:  Paul Eggleton; Lorna W Harries; Giada Alberigo; Paul Wordsworth; Nick Viner; Richard Haigh; Suzanne Donnelly; Hugh W Jones; Ian C Chikanza; Thomas W E O'Conner; Alasdair E R Thomson; Paul G Winyard
Journal:  J Clin Immunol       Date:  2010-06-09       Impact factor: 8.317

2.  Over-expression of the decoy receptor 3 (DcR3) gene in peripheral blood mononuclear cells (PBMC) derived from silicosis patients.

Authors:  T Otsuki; A Tomokuni; H Sakaguchi; T Aikoh; T Matsuki; Y Isozaki; F Hyodoh; H Ueki; M Kusaka; S Kita; A Ueki
Journal:  Clin Exp Immunol       Date:  2000-02       Impact factor: 4.330

Review 3.  Molecular mechanism of immune response, synovial proliferation and apoptosis in rheumatoid arthritis.

Authors:  T Hasunuma; T Kato; T Kobata; K Nishioka
Journal:  Springer Semin Immunopathol       Date:  1998

Review 4.  Optimisation of cyclophosphamide therapy in systemic vasculitis.

Authors:  R Richmond; T W McMillan; R A Luqmani
Journal:  Clin Pharmacokinet       Date:  1998-01       Impact factor: 6.447

5.  A role for the Fas antigen in lupus?

Authors:  A K Singh
Journal:  Postgrad Med J       Date:  1996-01       Impact factor: 2.401

6.  Synovial fibroblasts and the sphingomyelinase pathway: sphingomyelin turnover and ceramide generation are not signaling mechanisms for the actions of tumor necrosis factor-alpha.

Authors:  M E Gerritsen; C P Shen; C A Perry
Journal:  Am J Pathol       Date:  1998-02       Impact factor: 4.307

7.  Hydroxychloroquine potentiates Fas-mediated apoptosis of rheumatoid synoviocytes.

Authors:  W-U Kim; S-A Yoo; S-Y Min; S-H Park; H-S Koh; S-W Song; C-S Cho
Journal:  Clin Exp Immunol       Date:  2006-06       Impact factor: 4.330

8.  Combination of molecular mimicry and aberrant autoantigen expression is important for development of anti-Fas ligand autoantibodies in patients with systemic lupus erythematosus.

Authors:  S Mihara; N Suzuki; Y Takeba; K Soejima; S Yamamoto
Journal:  Clin Exp Immunol       Date:  2002-08       Impact factor: 4.330

9.  Ceramide, a mediator of interleukin 1, tumour necrosis factor alpha, as well as Fas receptor signalling, induces apoptosis of rheumatoid arthritis synovial cells.

Authors:  N Mizushima; H Kohsaka; N Miyasaka
Journal:  Ann Rheum Dis       Date:  1998-08       Impact factor: 19.103

10.  Comparison of the expression profile of apoptosis-associated genes in rheumatoid arthritis and osteoarthritis.

Authors:  Huang Qingchun; Huang Runyue; Jie LiGang; Chu Yongliang; Wei Song; Zhao Shujing
Journal:  Rheumatol Int       Date:  2008-02-15       Impact factor: 2.631

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.